ELAN - Elanco Animal Health Incorporated

NYSE - NYSE Delayed Price. Currency in USD
30.00
-0.61 (-1.99%)
At close: 4:05PM EST
Stock chart is not supported by your current browser
Previous Close30.61
Open30.61
Bid29.16 x 1000
Ask30.77 x 2200
Day's Range29.91 - 30.70
52 Week Range25.25 - 35.46
Volume5,121,675
Avg. Volume4,213,277
Market Cap11.418B
Beta (5Y Monthly)N/A
PE Ratio (TTM)119.05
EPS (TTM)0.25
Earnings DateFeb 18, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.50
  • Elanco (ELAN) Surges: Stock Moves 5.3% Higher
    Zacks

    Elanco (ELAN) Surges: Stock Moves 5.3% Higher

    Elanco (ELAN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • New Strong Sell Stocks for January 14th
    Zacks

    New Strong Sell Stocks for January 14th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • Hedge Fund Darlings vs. Elanco Animal Health Incorporated (ELAN) In 2019
    Insider Monkey

    Hedge Fund Darlings vs. Elanco Animal Health Incorporated (ELAN) In 2019

    It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity portfolio in 2019. However, if you were an […]

  • Business Wire

    Elanco Signs Agreement with PetIQ to Divest Capstar®

    Elanco Animal Health Incorporated (NYSE: ELAN) announced today it signed an agreement to divest the U.S. rights to Capstar®, an oral tablet that kills fleas in dogs and cats, to PetIQ, Inc. (Nasdaq: PETQ), a leading pet medication and wellness company, for $95 million in an all-cash deal. The product had 2018 revenue of $28.5 million.

  • GlobeNewswire

    PetIQ, Inc. Enters Into Definitive Agreement to Acquire the Capstar® portfolio of products from Elanco

    PetIQ, Inc. (“PetIQ” or the “Company”) (PETQ), a leading pet medication and wellness company, and Elanco today announced they have executed a definitive agreement under which PetIQ will acquire Capstar®, the #1 oral over-the-counter (“OTC”) flea treatment product in the United States, from Elanco Animal Health, Inc. (“Elanco”) (ELAN). The $95 million cash transaction has been unanimously approved by PetIQ’s and Elanco’s Board of Directors. PetIQ expects that this acquisition will be immediately accretive to earnings following the closing and thereafter.

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR

    Benzinga Pro's Stocks To Watch For Friday Eli Lilly (LLY)  - Shares were quiet Friday morning despite news the company will purchase  Dermira (DERM)  for $18.75/share in cash. Dermira shares were up about ...

  • MarketWatch

    Elanco Animal Health's stock falls after downbeat profit outlook

    Shares of Elanco Animal Health Inc. fell 0.9% in premarket trading Friday after the company provided 2020 profit guidance that was below analyst expectations. The company said it expects net earnings per share of 4 cents to 16 cents in 2020 and adjusted EPS, which excluding non-recurring items, of $1.09 to $1.16. The FactSet EPS consensus is $1.21. Elanco said it expects total revenue of $3.05 billion to $3.11 billion, compared with the FactSet consensus of $3.11 billion. For 2019, Elanco said the expected results are "consistent" with guidance provided in November, when the company said it expects adjusted EPS of $1.04 to $1.08 and total revenue of $3.070 billion to $3.085 billion. Elanco's stock has lost 11.2% over the past 12 months through Thursday, while the S&P 500 has gained 26.1%.

  • Business Wire

    Elanco Announces 2020 Financial Guidance

    Elanco Animal Health Incorporated (NYSE: ELAN) today announced its initial financial guidance for 2020, including total revenue expectations in the range of $3.05 billion to $3.11 billion, and Core Revenue, which excludes strategic exits, in the range of $3.00 billion to $3.06 billion. Elanco also expects earnings per share (EPS) for 2020 to be in the range of $0.04 to $0.16 on a reported basis and $1.09 to $1.16 on an adjusted basis. These revenue and EPS expectations are for stand-alone Elanco only, including full year revenues for products that may be divested, and do not include any expected revenues from the Bayer animal health business or impact of transactions related to the acquisition, such as potential issuance of additional shares.

  • Business Wire

    Elanco Confirms Date for 2020 Financial Guidance Announcement

    Elanco Animal Health Incorporated (NYSE: ELAN) will announce its financial guidance for 2020 on Friday, January 10, 2020. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s financial guidance.

  • Business Wire

    Elanco Signs Agreement with Dechra to Divest Osurnia®

    Elanco Animal Health Incorporated (NYSE: ELAN) announced today it has signed an agreement to divest Osurnia®, a treatment for otitis externa in dogs, to Dechra Pharmaceuticals PLC (LON: DPH) for $135 million in an all-cash deal.

  • Business Wire

    Elanco to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2020, in San Francisco, Calif. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts. He is scheduled to present at 12:30 p.m. ET (9:30 a.m. PT).

  • Business Wire

    Elanco Sells Victoria, PEI, Canada R&D Facility to The Center for Aquaculture Technologies Canada (CATC)

    Elanco Animal Health Incorporated (NYSE: ELAN) has signed an agreement to sell its Victoria, Prince Edward Island (PEI) aqua research and development facility to The Center for Aquaculture Technologies Canada, a leading aquaculture R&D and contract research services company with an established presence in PEI.

  • Zoetis Surges 45.3% YTD on Strong Portfolio & New Approvals
    Zacks

    Zoetis Surges 45.3% YTD on Strong Portfolio & New Approvals

    Zoetis (ZTS) surges on strong performance year to date, backed by a solid portfolio and prudent acquisitions.

  • Business Wire

    Elanco Animal Health Receives Second Request from FTC Under HSR Act

    Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has received a second request for information from the U.S. Federal Trade Commission (FTC) in regards to its previously announced acquisition of Bayer AG’s (ETR: BAYN) animal health business. The request was anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the review continues to progress as expected.

  • Should You Avoid Elanco Animal Health Incorporated (ELAN)?
    Insider Monkey

    Should You Avoid Elanco Animal Health Incorporated (ELAN)?

    "Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]

  • Business Wire

    Elanco Animal Health Appoints Chief Sustainability Officer, Emphasizes Continued Commitment to Advance Well-Being of Animals, People and Planet

    Elanco Animal Health Inc. (ELAN) today announced Sara Place, Ph.D., has joined the company as Chief Sustainability Officer, emphasizing the company’s continued commitment to make an impact on societal challenges by improving the health of animals. Place will join Elanco’s team of scientific experts: Chief Medical Officer Shabbir Simjee and Chief Animal Welfare Officer Michelle Calvo-Lorenzo. The group helps Elanco and its customers identify new opportunities to continue improving sustainable business practices, improve the well-being of animals and people, and reduce the environmental footprint of protein production by keeping food animals healthier.

  • Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio
    Zacks

    Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio

    Zoetis (ZTS) acquires ZNLabs and expands its reference laboratory capabilities in the United States.

  • Barrons.com

    Beyond Meat Is Shaking Up the Meat Industry. Animal-Health Stocks Could Take a Hit, Too.

    Wall Street has high hopes for the alternative-meat industry. If the world does end up eating less animal-based protein in the future, other industries—besides just meat producers—will be affected.

  • Investors Who Bought Elanco Animal Health (NYSE:ELAN) Shares A Year Ago Are Now Down 23%
    Simply Wall St.

    Investors Who Bought Elanco Animal Health (NYSE:ELAN) Shares A Year Ago Are Now Down 23%

    The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...

  • Benzinga

    Morgan Stanley Upgrades Elanco Animal Health On Valuation

    While Elanco Animal Health Inc’s (NYSE: ELAN ) current valuation reflects the ongoing investor concerns, the focus is now likely to shift to the positives related to the Bayer transaction, prospects of ...

  • Here's One Drugmaker That Popped On Earnings — And Two That Didn't
    Investor's Business Daily

    Here's One Drugmaker That Popped On Earnings — And Two That Didn't

    Shares of Ionis Pharma jumped Wednesday after the biotech's third-quarter sales and profit easily topped Wall Street's estimates. But Perrigo and Elanco stocks dipped after their reports.

  • Business Wire

    Elanco Animal Health Reports Third Quarter Results

    GREENFIELD, Ind.-- -- Earnings per share was $0.03 , or $0.30 for the third quarter 2019, including a benefit of $0.02 from a tax item Gross margin improved to 53.3 percent of revenue , an improvement of 190 basis points and 210 basis points for the third quarter 2019 Total Revenue in the third quarter of 2019 increased 1 percent to $771.3 million; Total and Core Revenue grew 2 percent and 4 percent, ...

  • Healthcare Stock Earnings Slated on Nov 6: HUM, ELAN & More
    Zacks

    Healthcare Stock Earnings Slated on Nov 6: HUM, ELAN & More

    Rise in senior population, shift of care to lower-cost settings and decline in unemployment are likely to have driven healthcare sector earnings.

  • Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q3 Earnings Expected to Decline
    Zacks

    Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q3 Earnings Expected to Decline

    Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.